 
 
November 16, 2025 
 
BSE Limited 
P J Towers,  
Dalal Street, 
Mumbai – 400 001 
 
Scrip Code: 543904 
National Stock Exchange of India Limited 
Exchange Plaza, C-1, Block G, 
Bandra Kurla Complex, 
Bandra (E), Mumbai – 400 051 
 
Symbol: MANKIND 
 
Dear Sir/ Madam, 
 
Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure   
Requirements) Regulations, 2015 (“Listing Regulations”) 
 
 
Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, this is to inform you 
that the Mankind Pharma Limited (“Company”) has received an order for Financial Year 2018-19 
& 2019-20, on November 15, 2025 from Office of the Assistant Commissioner, Cuttack 
(“Department”), in respect of erstwhile M/s Lifestar Pharma Private Limited, a wholly owned 
subsidiary of the Company which now stands merged with the Company, under the applicable 
provisions of the GST Act.  
 
Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid 
order is arbitrary and unjustified. The Company will file necessary appeal with the appellate 
authority in this regard. There is no material impact on financials, operations or other activities of 
the Company. 
 
The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI 
Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as 
Annexure-I. 
  
This is for your information and records. 
 
Thanking You, 
 
Yours Faithfully, 
 
For Mankind Pharma Limited 
 
 
 
Hitesh Kumar Jain 
Company Secretary & 
Compliance Officer 
 
 
 
 
 
Annexure-I 
Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations 2015 read with SEBI Master Circular No. 
SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024: 
 
Sr. 
No. 
Particulars of Information required to 
be provided 
Details 
1 Name of the authority  Assistant Commissioner, GST & Central Excise, 
Cuttack (“Department”)  
2 Nature and details of the action(s) taken, 
initiated or order(s) passed 
The Company has received an Order, in respect of 
erstwhile M/s Lifestar Pharma Private Limited, a 
wholly owned subsidiary of the Company which 
now stands merged with the Company from the 
Odisha GST Authority imposing penalty of INR 
22,16,148/- under applicable provisions of the 
CGST Act, 2017, SGST Act, 2017 and IGST Act, 
2017 for Financial Year 2018-19 & 2019-20. 
3 Date of receipt of direction or order, 
including any ad-interim or interim 
orders, or any other communication from 
the authority;  
 
 
November 15, 2025  
4 Details of the 
violation(s)/contravention(s) committed 
or alleged to be committed;  
  
The Order has been passed on the contention that 
there is an alleged mismatch in the ITC figures 
reported in the GST return. 
5 Impact on financial, operation or other 
activities of the listed entity, quantifiable 
in monetary terms to the extent possible;  
 
Based on the assessment of facts and prevailing 
law, the Company is of the view that the demand 
including penalty levied is arbitrary and 
unjustified.  
 
The Company does not agree with the order and 
will take appropriate action(s) for the same 
including filing of an appeal if required. 
 
There is no material impact on the company's 
financials, operations, or other activities.  
 
 
